Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ajinomoto completes acquisition of Althea Technologies
All the capital stock of Althea is purchased by Ajinomoto at closing for approximately $175m. Althea will turn out to be a fully consolidated subsidiary of Ajinomoto, doing
All the capital stock of Althea is purchased by Ajinomoto at closing for approximately $175m. Althea will turn out to be a fully consolidated subsidiary of Ajinomoto, doing
GenePrint10 consists of the eight loci recommended by the ANSI Standard (ASN-0002) Authentication of Human Cell Lines: Standardization of STR Profiling, plus Amelogenin for gender identification and the
The patent describes the format and methodology of T2Candida test, desinged to detect and identify Candida species in a blood sample. T2Candida will identify sepsis-causing Candida species directly
The AG Mednet Submission Quality and Compliance module will detect errors that result in query stoppages and offer ICLs a system to check information, automatically update support systems
Privigen is an immune globulin intravenous [human], 10% liquid, developed for intravenous administration in CIDP patients. CSL Behring research and development senior vice president Val Romberg said it
Randomized, double-blind study will assess ixmyelocel-T’s efficacy and safety in treating patients with advanced heart failure due to ischemic dilated cardiomyopathy. Aastrom Biosciences acting chief medical officer David
The company’s US-based distributor Covis Pharmaceuticals will promote the products, manufactured and supplied by Sanofi, in the US. Sanofi retains the rights for the products outside US. Covis
As per the deal, Aragen is developing CHO cell lines in addition to estimating the characteristics for various antibodies and protein therapeutics. Innovent CEO Michael Yu said Aragen
Ambrx will use site-specific conjugation technology in addition to proprietary linkers and payloads to produce optimized ADCs, which will then be developed and commercialized by Astellas. Agensys site
The solution is used to plan, track and report on clinical trials and is available as a hosted, software-as-a-service (SaaS) application. The Impact CTMS features improved data entry